After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week.

AI in Biotechnology Market worth $22,716.5 million by 2035 with 18.5% CAGR | MarketsandMarkets (TM).

Recursion Pharmaceuticals ( RXRX 1.39%) has been a pioneer in using artificial intelligence (AI) to improve the drug ...

The early modern physicist Isaac Newton had presumed an unperceived yet real flow of time. To Newton, time is a dynamic ...

A patchwork of internet communities is devoted to the project of ‘awakening’ more digital companions through arcane and enigmatic prompts.

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

Abstract: The Plotkin construction combines two codes to a code of doubled length. It can be applied recursively. The class of Reed-Muller (RM) codes is a particular example. Exploiting a property of ...

Gibson highlighted, "Recursion has a tremendous amount of potential catalysts coming in the next 18 months," referencing the pipeline, partnerships, and platform advancements. He reported, "a pro ...

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.34 per share a year ago. These ...

Recursion CEO Chris Gibson is out after 12 years as the ambitious "techbio" company positions itself for its next phase of AI drug discovery.

Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board ...

SALT LAKE CITY, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding ...